Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
British Journal of Cancer|September 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosisAbderaouf Hamza, Pierre Gestraud, Maryam Karimi, et al.
British Journal of Cancer|August 1, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitorsMarie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2012
Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2Anne Rullier, Sophie Gourgou-Bourgade, Marta Jarlier, et al.
Science Immunology|July 31, 2021
Human γδ T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2Christelle Harly, Stephen Paul Joyce, Charlotte Domblides, et al.
Nature Communications|August 30, 2024
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockadeMarie-Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
Genes, Chromosomes & Cancer|March 14, 2024
Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretationQuitterie Fontanges, Paul Dubos, Tom Lesluyes, et al.
BMC Cancer|November 6, 2021
Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trialAntoine Italiano, Derek Dinart, Isabelle Soubeyran, et al.
The Journal of Clinical Investigation|April 23, 2024
Human NLRC4 expression promotes cancer survival and associates with type I interferon signaling and immune infiltrationCharlotte Domblides, Steven Crampton, Hong Liu, et al.
The Lancet. Haematology|December 15, 2016
Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trialFrançoise Kraeber-Bodere, Amandine Pallardy, Hervé Maisonneuve, et al.
ESMO Open|July 28, 2020
Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan, Céline Auzanneau, Delphine Bacq, et al.
Pageof 10